Precision Research ChemicalsThird-Party TestedBatch-Specific CoASame-Day Shipping14 Compounds99%+ Purity
Precision Research ChemicalsThird-Party TestedBatch-Specific CoASame-Day Shipping14 Compounds99%+ Purity
KERN
Shop/Tesamorelin
Tesamorelin (10mg)

Tesamorelin

Synthetic GHRH analog. FDA-approved version (Egrifta) indicated for HIV-associated lipodystrophy. Research analog for in vitro study.

Quantity

3
$405.95$418.50USD

Bundle & Save

Batch-Specific CoA
Third-Party Tested
Same-Day Shipping
We acceptVisaMastercardAmerican ExpressBitcoin

Research Use Only. This product is intended for laboratory research purposes only. Not for human or veterinary use. Not for sale to minors.

Certificate of Analysis

Latest

Independent third-party analytical certificates for Tesamorelin. A batch-specific CoA is provided with every purchase.

01At a Glance01 / 08

Tesamorelin — Key Data

A snapshot of published research on Tesamorelin. Each figure links to the literature summarized below.

Approved (Egrifta)
0November 2010 for HIV-associated lipodystrophy
Visceral Fat Reduction
026 weeks, n=412 (Falutz et al., NEJM)
IGF-1 Increase
0+109 ng/mL in 26 weeks
Executive Function
0Cognitive improvement in adults 55-87 (Baker et al.)
Liver Fat Reduction
0NAFLD resolution: 35% vs 4% placebo
02Mechanism02 / 08

How Tesamorelin Works

Tesamorelin is a synthetic GHRH analog with an FDA-approved version (Egrifta) indicated for HIV-associated lipodystrophy. It reduces visceral adipose tissue by 15.2% over 26 weeks, increases IGF-1 by 81%, and has shown cognitive benefits in adults 55-87 (executive function p = .005). It also reduced liver fat by 37% and prevented fibrosis progression (10% vs 37% placebo). For research use only.

Discovered ~2000s100+ publicationsTheratechnologies (Montreal); FDA-approved as Egrifta (2010)

  1. 01

    GHRH Receptor Activation

    Primary
    • Stimulates endogenous GH release from pituitary
    • +81% IGF-1 increase (+109 ng/mL in 26 weeks)
    • 15.2% visceral fat reduction (n=412, NEJM)
  2. 02

    Hepatic / Cognitive Effects

    Secondary
    • 37% relative liver fat reduction vs placebo
    • NAFLD resolution: 35% tesamorelin vs 4% placebo
    • Executive function improvement (p = .005) in adults 55-87
03Findings03 / 08

What the Studies Show

Peer-reviewed outcomes from published Tesamorelin research.

0

n=412, 2mg SC daily for 26 weeks. vs 5.0% increase in placebo group.

Falutz et al., 2007 (NEJM)

Additional Clinical Outcomes

  1. 0

    152 adults aged 55-87 (76 healthy, 61 MCI). 1 mg/day SC for 20 weeks. Overall cognition p = .03 (ITT), p = .002 (completers).

    Baker et al., 2012
  2. 0

    12-month study (n=61, HIV+ with NAFLD). Tesamorelin prevented fibrosis progression (p = 0.044). Hepatic fat fraction reduced 37% relative to placebo.

    Stanley et al., 2019

GHRH Analog Comparison

FDA-approved, 44aa + hexenoic acid
Tesamorelin
29aa, shorter half-life
Sermorelin
29aa modified, DPP-IV resistant
CJC-1295 (No DAC)

Tesamorelin is the only GHRH analog with FDA approval and published NEJM data

04Applications04 / 08

Research Applications

Reported areas of investigation across the Tesamorelin literature.

  1. 01
    VISCERAL FAT

    15.2% Visceral Fat Reduction (NEJM)

    412 patients, 2mg SC daily for 26 weeks. vs 5.0% increase in placebo group. Published in the New England Journal of Medicine.

    VAT reduction
    -15.2%
    Placebo change
    +5.0%
    Patients
    412

    Study finding. IGF-1 increased 81% (+109 ng/mL) over 26 weeks.

    Falutz et al., 2007 (NEJM)
  2. 02
    COGNITIVE FUNCTION

    Executive Function Improvement

    152 adults aged 55-87 (76 healthy, 61 MCI). 1 mg/day SC for 20 weeks. Executive function p = .005, overall cognition p = .03.

    Executive function
    p = .005
    Overall cognition (ITT)
    p = .03
    Overall (completers)
    p = .002

    Study finding. Both healthy adults and those with mild cognitive impairment showed improvement.

    Baker et al., 2012
  3. 03
    LIVER HEALTH

    NAFLD Resolution and Fibrosis Prevention

    37% relative liver fat reduction. NAFLD resolution: 35% tesamorelin vs 4% placebo. Fibrosis progression: 10% vs 37% placebo.

    Liver fat reduction
    -37%
    NAFLD resolution
    35% vs 4%
    Fibrosis progression
    10% vs 37% (p=0.044)

    Study finding. 12-month study (n=61, HIV+ with NAFLD). Tesamorelin prevented fibrosis progression.

    Stanley et al., 2019
05Safety05 / 08

Reported Observations

  • FDA-approved medication (Egrifta) since November 2010
  • 34% of patients had IGF-1 SDS >2 at 52 weeks (monitoring required)
  • IGF-1 levels maintained at 26-week levels through week 52

This summary reflects observations from published peer-reviewed research. It is not a comprehensive safety assessment. Researchers should review primary literature before designing protocols. For Research Use Only.

06Compound06 / 08

Compound Profile

Molecular Profile

What Is Tesamorelin?

TypeSynthetic Peptide (GHRH Analog + Trans-3-Hexenoic Acid)
CAS Number218949-48-5
Molecular Weight5,135.76 g/mol
Amino Acids44 (human GHRH + hexenoic acid modification)
FormulaC221H366N72O67S
View on PubChem
Storage & Handling

Stability Information

  • Protect from light
  • Avoid repeated freeze-thaw cycles
  • Store in original sealed container

Lyophilized (powder)

up to 2 years

-20°C

Reconstituted

up to 30 days

2-8°C

Working solution

Use within 24 hours

Room temp
07Questions07 / 08

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of all 44 amino acids of human GHRH with an added trans-3-hexenoic acid group at the N-terminus. The FDA-approved version (Egrifta) is indicated for the reduction of excess abdominal fat in HIV-associated lipodystrophy. It is one of the few GH secretagogues with FDA approval for any indication. The research-grade form is used for in vitro and preclinical studies.

Both are GHRH analogs but differ in pharmacokinetics and regulatory status. Tesamorelin is FDA-approved (for HIV lipodystrophy), has a shorter half-life requiring daily administration, and has the strongest published evidence for visceral fat reduction. CJC-1295 (especially with DAC) has an extended half-life allowing less frequent dosing but lacks FDA approval and has fewer published clinical studies. Tesamorelin has the deeper evidence base; CJC-1295 offers more practical dosing flexibility.

Phase 3 clinical trials demonstrated a 15% reduction in visceral adipose tissue after 26 weeks of daily 2mg subcutaneous administration, with results maintained through 52 weeks of treatment. These are among the most robust clinical data available for any GH secretagogue in the context of body composition research.

The FDA label for Egrifta lists injection-site reactions, itching, joint pain (arthralgia), muscle pain (myalgia), and peripheral edema as the most common adverse events. The compound is generally well-tolerated in published clinical data.

Emerging research has investigated Tesamorelin's effects on cognitive function and neurodegeneration biomarkers. Some studies have reported improvements in cognitive markers, but this research is still preliminary. The compound's primary evidence base remains in body composition and metabolic health.

Store lyophilized Tesamorelin at -20C. Reconstitute with bacteriostatic water and refrigerate at 2-8C. Use reconstituted vials within 30 days.

Every batch undergoes third-party HPLC and mass spectrometry testing. HPLC confirms purity (99%+ standard). Mass spectrometry confirms molecular identity. A batch-specific Certificate of Analysis is provided with every purchase and available for download directly on this page.

All Kern products ship same-day (orders placed before 1pm EST). Lyophilized peptides are shipped at ambient temperature and are stable during transit. Upon receipt, store at -20C for long-term stability or 2-8C for near-term use. If the product arrives damaged, contact us within 7 days with photos for a free replacement.

Price differences usually reflect differences in purity, testing standards, and manufacturing quality. Low-cost vendors may skip mass spectrometry verification (which confirms you actually have the right molecule), use lower-grade raw materials, or skip sterility and endotoxin testing. Kern tests every batch with both HPLC and mass spec, and our CoAs are available before you buy.

08References08 / 08

References

These references are provided for informational purposes. Kern is not affiliated with the authors or institutions listed above.

Related Products

Important Notice — Please Read

The statements made within this website have not been evaluated by the US Food and Drug Administration. The products we offer are not intended to diagnose, treat, cure, or prevent any disease. The peptides sold on this website are intended for research use only. The buyer is responsible for adhering to all local laws and regulations. Kern is not a pharmacy and does not provide medical advice or prescriptions. They are not for human consumption, are not FDA approved, and are not supplements or pharmaceutical drugs. The information provided on this website is for informational purposes and not a substitute for professional medical advice, diagnosis, or treatment. If you have questions or concerns about your health, please talk to your doctor. This site is an advertisement for education, research peptides, and not any specific medication. By purchasing from Kern, you confirm that you are a qualified researcher purchasing these compounds for legitimate in vitro or laboratory research purposes only. You must be 21 years of age or older to purchase.